• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation.
【24h】

Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation.

机译：同种异体造血干细胞移植后的供体淋巴细胞输注。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Allogeneic hematopoietic stem cell transplantation (SCT) is the treatment of choice for many malignant hematological disorders. Following recent improvements in non-relapse-related mortality rates, relapse has become the commonest cause of treatment failure. Infusion of donor lymphocytes can potentially enhance immune-mediated antitumor activity and offers a salvage option for some patients. This paper reviews the current literature on the efficacy of this therapeutic strategy. AREAS COVERED: The biology of adoptive cellular therapy with allogeneic immune cells to treat relapse across a spectrum of diseases in both the full intensity and reduced intensity hematopoietic SCT settings is explored. The review discusses the current limitations of the approach and reviews several new experimental strategies which aim to segregate the desired graft-versus-tumor effect from the deleterious effects of more widespread graft-versus-host reactivity. EXPERT OPINION: Durable responses to DLI have been noted in chronic myeloid leukemia and responses have also been described in acute leukemia, multiple myeloma and chronic lymphoproliferative disorders. The new challenge in transplantation is to optimize DLI therapy in order to further improve patient outcomes.
机译：简介：同种异体造血干细胞移植（SCT）是许多恶性血液学疾病的首选治疗方法。随着近期非复发相关死亡率的改善，复发已成为治疗失败的最常见原因。输注供体淋巴细胞可以潜在地增强免疫介导的抗肿瘤活性，并为某些患者提供挽救的选择。本文回顾了有关这种治疗策略功效的最新文献。覆盖的领域：探索了采用同种异体免疫细胞进行过继性细胞治疗的生物学方法，该方法可在全强度和降低强度的造血SCT环境中治疗多种疾病的复发。审查讨论了该方法的当前局限性，并审查了几种旨在将所需的移植物抗肿瘤效应与更广泛的移植物抗宿主反应性的有害效应区分开的新实验策略。专家意见：在慢性粒细胞白血病中已注意到对DLI的持久反应，在急性白血病，多发性骨髓瘤和慢性淋巴细胞增生性疾病中也已描述了对DLI的反应。移植中的新挑战是优化DLI治疗，以进一步改善患者预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号